Chinese Radiopharma Developers Continue Fundraising Spree

 
• By Dexter Jie Yan

Reflecting global interest in the field, Chinese radiopharma specialists PharmadaX Genesis, LNC Biotechnology and SmartNuclide have been on a winning streak to secure venture capital funding. Separately, Impact and Arnatar raised around $50m each in their latest venture capital- and private equity-backed fundraisings.

funding
Three Chinese radiopharmaceutical ventures close major funding rounds within past month • Source: Shutterstock

More from China

More from Focus On Asia